Viroblock pulls in first-round funding

July 20, 2007 | David P. Hamilton

Viroblock, a Geneva-based biotech focused on new antiviral drugs, raised a first round of funding. The company didn’t disclose financial details; its release is here. The round was led by private investor Peter Pfister, Fongit Seed Invest, and Initiative Capital Romandie.

The company is developing new ways for attacking “enveloped” viruses, whose DNA or RNA genomes are wrapped in some form of protein coat. A Viroblock official said in a statement that the funding will allow the company to move from Petri-dish experiments to animal tests.

Next Story: ImaRx: A blood-clot attacker with sinking IPO hopes
Previous Story: Inverness acquires 51% of diagnostics maker Diamics

Twitter

Facebook

Google Buzz

Digg

StumbleUpon

Delicious

Google

More...

Tags: antivirals, biotechnology, deal, Initiative Capital Romandie

About the Author, David P. Hamilton

David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.